Institutional Ownership
Tvardi Therapeutics Inc
CUSIP 140755307COMTVRDQ1 2026
13D / 13G Filings
3
Schedule 13D/13G on record
Beneficial Filers
3
Distinct reporting persons
Largest Stake
7.5%
Max % of class reported
Institutional Holders
63
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
3 filings · latest Feb 17, 2026
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Slate Path Capital LP | 704.1K | $2.24M |
| 2 | Blackrock, Inc. | 388.1K | $1.23M |
| 3 | American Financial Group Inc | 223.7K | $711.2K |
| 4 | Geode Capital Management, LLC | 182.3K | $580.0K |
| 5 | Silvercrest Asset Management Group LLC | 101.0K | $321.3K |
| 6 | State Street Corp | 97.2K | $309.2K |
| 7 | Renaissance Technologies LLC | 92.1K | $292.9K |
| 8 | Morgan Stanley | 72.9K | $231.8K |
| 9 | Duncan Williams Asset Management, LLC | 63.2K | $201.1K |
| 10 | Ubs Group AG | 50.5K | $160.4K |